

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Proposed Single Technology Appraisal Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• ChemoCentryx (avacopan)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Arthritis Care</li> <li>• Asthma UK</li> <li>• British Kidney Patient Association</li> <li>• British Lung Foundation</li> <li>• Lauren Curie Twilight Foundation</li> <li>• Lupus UK</li> <li>• Muslim Council of Britain</li> <li>• National Kidney Federation</li> <li>• National Rheumatoid Arthritis Society</li> <li>• Rare Disease UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Vasculitis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Renal Technologists</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• Association of Respiratory Technology and Physiology</li> <li>• British Association for Urological Surgeons</li> <li>• British Association of Dermatologists</li> <li>• British Association of Urological Nurses</li> <li>• British Renal Society</li> <li>• British Society for Rheumatology</li> <li>• British Thoracic Society</li> <li>• Primary Care Respiratory Society UK</li> <li>• Primary Care Rheumatology Society</li> <li>• Renal Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord (methotrexate, mycophenolate, prednisolone)</li> <li>• Allergan (azathioprine, mycophenolate, prednisolone)</li> <li>• Aspen Medical Europe (azathioprine)</li> <li>• Baxter Healthcare (cyclophosphamide)</li> <li>• Concordia International (methotrexate, prednisolone)</li> <li>• Hameln Pharmaceutical (methotrexate)</li> <li>• Hospira UK (methotrexate)</li> <li>• Intrapharm Laboratories (prednisolone)</li> <li>• Logixx Pharma Solutions (prednisolone)</li> <li>• Medac UK (methotrexate)</li> <li>• Mylan UK (azathioprine)</li> <li>• Napp Pharmaceuticals (prednisone)</li> </ul>

National Institute for Health and Care Excellence  
Provisional matrix for the proposed technology appraisal of avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for DGH Nephrologists</li> <li>• Society of Vascular Nurses</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• UK Renal Pharmacy Group</li> <li>• Urology Foundation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Lewisham CCG</li> <li>• NHS Milton Keynes CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Nordic Pharma (methotrexate)</li> <li>• Orion Pharma (UK) (methotrexate)</li> <li>• Pfizer (methotrexate)</li> <li>• Roche Products (mycophenolate, rituximab)</li> <li>• Rosemont Pharmaceuticals Limited (methotrexate)</li> <li>• Sandoz (azathioprine, methotrexate, cyclophosphamide, mycophenolate)</li> <li>• Wockhardt UK (prednisolone)</li> <li>• Zentiva UK (prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Arthritis Research UK</li> <li>• British Association for Lung Research</li> <li>• Cochrane Airways Group</li> <li>• Cochrane Acute Respiratory Infections Group</li> <li>• Cochrane Kidney and Transplant Group</li> <li>• Cochrane Musculoskeletal Group</li> <li>• Cochrane Skin Group</li> <li>• Cochrane Vascular</li> <li>• MRC Clinical Trials Unit</li> <li>• Kidney Research UK</li> <li>• National Institute for Health Research</li> <li>• Skin Research Centre</li> <li>• Skin Treatment and Research Trust</li> <li>• Vasculitis Rare Disease Working Group of the UK and Ireland</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

National Institute for Health and Care Excellence  
Provisional matrix for the proposed technology appraisal of avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.